| Title |
Economic Evaluation of First-Line Adjuvant Chemotherapies for Resectable Gastric Cancer Patients in China
|
|---|---|
| Published in |
PLOS ONE, December 2013
|
| DOI | 10.1371/journal.pone.0083396 |
| Pubmed ID | |
| Authors |
Chongqing Tan, Liubao Peng, Xiaohui Zeng, Jianhe Li, Xiaomin Wan, Gannong Chen, Lidan Yi, Xia Luo, Ziying Zhao |
| Abstract |
First-line postoperative adjuvant chemotherapies with S-1 and capecitabine and oxaliplatin (XELOX) were first recommended for resectable gastric cancer patients in the 2010 and 2011 Chinese NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer; however, their economic impact in China is unknown. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 37 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 6 | 16% |
| Researcher | 6 | 16% |
| Student > Master | 6 | 16% |
| Other | 4 | 11% |
| Student > Doctoral Student | 2 | 5% |
| Other | 3 | 8% |
| Unknown | 10 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 35% |
| Agricultural and Biological Sciences | 2 | 5% |
| Psychology | 2 | 5% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
| Other | 4 | 11% |
| Unknown | 14 | 38% |